Abstract
Abstract: :
Purpose: Because of the controversy surrounding possible adverse side effects as a result of topical latanoprost (Lat), anti-glaucoma eyedrop of prostaglandin F2a analog, usage on patients with uveitis, we examined the influence of topical Lat on the severity of experimental autoimmune uveitis (EAU) in rats. Methods: EAU was induced with 50µg of S-Ag peptide in Lewis rats. Sixty rats were divided into four groups (Group1: benzalkonium chloride (vehicle) only, Group2: Lat, Group3: Dexamethazone (DEX)+vehicle, Group4: DEX+Lat, each n=15). 10µl of eyedrop was applied each time. Dex was applied twice a day, Lat and vehicle were applied once a day. The onset and severity of EAU were monitored with a slit lamp everyday and evaluated by the combined EAU score (0-4 in each eye) of both eyes. Results: The average days of the onsets of EAU were 9.8±0.9, 10.4±1.1, 16.3±3.9, and 14.7±2.2 in Groups 1-4, respectively. The peak of EAU was observed on day 12, 12, 16, and 17, respectively . The peak values of the EAU score were 7.1±0.2, 6.1±0.6, 3.0±0.8, and 3.3±0.7 (average ± standard error ), respectively. There were no significant differences of the onset day and the peak values of EAU score in Group 1 vs Group 2, and in Group 3 vs Group 4. Conclusions: Obvious adverse side effects of topical latanoprost on EAU were not detected clinically in this study. Pathological examinations are currently in progress to further elucidate the issue.
Keywords: uveitis-clinical/animal model • pharmacology • inflammation